Dank dem Mann, der diese Nacht den Baby Dienst vollständig übernommen hat (normal teilen wir 50:50) hab ich fast 9 Stunden Schlaf bekommen und fühle mich jetzt halbwegs bereit für den Tag.
Die Maus bekommt gleich 4 Impfungen* auf einmal, ich werd’s brauchen 🫣
* 6-fach, MenB, Rota, Pneumokokken
Die Maus bekommt gleich 4 Impfungen* auf einmal, ich werd’s brauchen 🫣
* 6-fach, MenB, Rota, Pneumokokken
January 27, 2026 at 7:22 AM
Dank dem Mann, der diese Nacht den Baby Dienst vollständig übernommen hat (normal teilen wir 50:50) hab ich fast 9 Stunden Schlaf bekommen und fühle mich jetzt halbwegs bereit für den Tag.
Die Maus bekommt gleich 4 Impfungen* auf einmal, ich werd’s brauchen 🫣
* 6-fach, MenB, Rota, Pneumokokken
Die Maus bekommt gleich 4 Impfungen* auf einmal, ich werd’s brauchen 🫣
* 6-fach, MenB, Rota, Pneumokokken
Uuuh. Bravo! MenB potrebbe stenderti!
January 23, 2026 at 10:24 AM
Uuuh. Bravo! MenB potrebbe stenderti!
Amore vaccino per HPV e MenB
January 23, 2026 at 10:04 AM
Amore vaccino per HPV e MenB
In our new issue, @flahless.bsky.social and colleagues describe clinical presentation, transmission dynamics, #PublicHealth response & phylogenetic analysis of the first local transmission of #MPXV clade Ib virus in the Netherlands
🗞️ bit.ly/EUS313
#EpiSky #IDSky #MedSky #MicroSky 🛟🧪 #mpox #AMR
🗞️ bit.ly/EUS313
#EpiSky #IDSky #MedSky #MicroSky 🛟🧪 #mpox #AMR
January 23, 2026 at 9:58 AM
In our new issue, @flahless.bsky.social and colleagues describe clinical presentation, transmission dynamics, #PublicHealth response & phylogenetic analysis of the first local transmission of #MPXV clade Ib virus in the Netherlands
🗞️ bit.ly/EUS313
#EpiSky #IDSky #MedSky #MicroSky 🛟🧪 #mpox #AMR
🗞️ bit.ly/EUS313
#EpiSky #IDSky #MedSky #MicroSky 🛟🧪 #mpox #AMR
January 23, 2026 at 7:22 AM
First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023 - www.eurosurveillance.org/content/10.2...
Eurosurveillance | First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023
In November 2023, the UK Health Security Agency was notified of PCR-confirmed group B (MenB) invasive meningococcal disease (IMD) in a 3-year-old child (Case A), followed by probable IMD in a 2-year-old (Case B, culture and PCR tests negative) attending the same nursery. An incident management team (IMT) was convened. Both children were fully vaccinated with the MenB vaccine 4CMenB (Bexsero, GSK Biologicals). All 39 children attending the nursery and nine staff received ciprofloxacin chemoprophylaxis preceded by pharyngeal swabbing. Pharyngeal swabbing yielded two MenB isolates matching Case A. Antibiotic sensitivity testing and assessment of 4CMenB vaccine coverage using the meningococcal antigen typing system (MATS) revealed the strain was not covered by the 4CMenB vaccine. Although the alternative MenB vaccine, MenB-fHbp (Trumenba, Pfizer), is only licensed from 10 years and has never been given to children previously immunised with 4CMenB, the IMT considered the benefits of outbreak control outweighed potential risks. Two doses were given 4 weeks apart to 38 children (one family declined) and all staff; there were no serious adverse events. Our findings highlight the utility of swabbing to identify outbreak strains and provide first evidence for safe use of the MenB-fHbp vaccine in children previously vaccinated with 4CMenB.
www.eurosurveillance.org
January 23, 2026 at 3:41 AM
First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023 - www.eurosurveillance.org/content/10.2...
Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a recent MMWR. #IDsky #Medsky
www.contagionlive.com/view/-modera...
www.contagionlive.com/view/-modera...
"Moderate" Evidence Supports Latest Pentavalent Meningococcal Vaccine as Alternative to Separate Quadrivalent and MenB | Contagion Live
Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a rece...
www.contagionlive.com
January 16, 2026 at 4:18 PM
Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a recent MMWR. #IDsky #Medsky
www.contagionlive.com/view/-modera...
www.contagionlive.com/view/-modera...
ICYMI: Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
A vaccine against serogroup B meningococcal disease has been prepared from a B:15:P1.7,16 meningococcal strain (44/76) by fermentor growth and extraction of the bacteria with the detergent deoxycholate. Outer membrane vesicles (OMV) were pu...
eurekamag.com
January 14, 2026 at 7:39 AM
ICYMI: Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
What a fantastic helpful response, thanks! Have been very ambivalent about MenB shared decision-making recs for “college”. Seems newer combo vax with acyw+b at age 16 might not even cover college years well for menB. Hmm …
January 13, 2026 at 8:02 PM
What a fantastic helpful response, thanks! Have been very ambivalent about MenB shared decision-making recs for “college”. Seems newer combo vax with acyw+b at age 16 might not even cover college years well for menB. Hmm …
This is why MenB is used for short-term risk reduction (outbreaks, specific exposures), not long-term population immunity and why routine boosters aren’t broadly recommended unless risk persists.
January 13, 2026 at 7:55 PM
This is why MenB is used for short-term risk reduction (outbreaks, specific exposures), not long-term population immunity and why routine boosters aren’t broadly recommended unless risk persists.
MenB is even more complicated. MenB vaccines induce narrower, strain-specific responses, rely on protein antigens with variable expression, show faster waning of functional protection (often within 1–2 years).
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine | Clinical and Vaccine Immunology
ABSTRACT MenB-FHbp is a meningococcal serogroup B vaccine with two factor H binding protein
(FHbp) antigens from subfamilies A and B. For licensure, efficacy was inferred from
serum bactericidal antib...
journals.asm.org
January 13, 2026 at 7:55 PM
MenB is even more complicated. MenB vaccines induce narrower, strain-specific responses, rely on protein antigens with variable expression, show faster waning of functional protection (often within 1–2 years).
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Had the 2nd MenB jab today, o can really feel it in my arm
I’ve had flap all sleep but I’ve made it to my appointment for a jab and more PrEP
January 13, 2026 at 7:34 PM
Had the 2nd MenB jab today, o can really feel it in my arm
Curious about MenACYW and MenB ... how convinced are we that effectiveness wanes? Not just titers, as with other shots titers drop and don't mean lack of immunity since we expect memory B-cells etc to still protect?
January 13, 2026 at 7:25 PM
Curious about MenACYW and MenB ... how convinced are we that effectiveness wanes? Not just titers, as with other shots titers drop and don't mean lack of immunity since we expect memory B-cells etc to still protect?
The MenB vaccine huuuuuurts.
Much ache. Such ow.
Much ache. Such ow.
January 13, 2026 at 5:35 PM
The MenB vaccine huuuuuurts.
Much ache. Such ow.
Much ache. Such ow.
What they find most frustrating is I haven't complied, accomplished things they didn't expect while chip.ca 'in away at their three legged stool weakening them minimally though consistently over time. Now they're on the line instead of "Hold'n The Line and demanding meNB
share.google/Y02orhXd4ouc...
share.google/Y02orhXd4ouc...
chip.ca
January 13, 2026 at 2:05 PM
What they find most frustrating is I haven't complied, accomplished things they didn't expect while chip.ca 'in away at their three legged stool weakening them minimally though consistently over time. Now they're on the line instead of "Hold'n The Line and demanding meNB
share.google/Y02orhXd4ouc...
share.google/Y02orhXd4ouc...
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
A vaccine against serogroup B meningococcal disease has been prepared from a B:15:P1.7,16 meningococcal strain (44/76) by fermentor growth and extraction of the bacteria with the detergent deoxycholate. Outer membrane vesicles (OMV) were pu...
eurekamag.com
January 13, 2026 at 7:38 AM
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease
Today's report covers April 2025 recommendations from ACIP on the newest MenABCWY vaccine: it can be used instead of giving two vaccines (MenACWY plus MenB) for:
✅ high risk kids ≥10 yrs who need both ACWY and B coverage
✅ healthy people 16–23 yrs who want both ACWY and B coverage per shared CDM
✅ high risk kids ≥10 yrs who need both ACWY and B coverage
✅ healthy people 16–23 yrs who want both ACWY and B coverage per shared CDM
January 9, 2026 at 2:00 AM
Today's report covers April 2025 recommendations from ACIP on the newest MenABCWY vaccine: it can be used instead of giving two vaccines (MenACWY plus MenB) for:
✅ high risk kids ≥10 yrs who need both ACWY and B coverage
✅ healthy people 16–23 yrs who want both ACWY and B coverage per shared CDM
✅ high risk kids ≥10 yrs who need both ACWY and B coverage
✅ healthy people 16–23 yrs who want both ACWY and B coverage per shared CDM
Prior to 2023, the US had 4 licensed meningitis vaccines: 2 covered serogroups A, C, W, and Y (MenACWY vaccine) and 2 covered serogroup B (MenB vaccine).
In 2023, the FDA licensed two vaccines that cover A, C, W, Y and B (MenABCWY vaccine).
In 2023, the FDA licensed two vaccines that cover A, C, W, Y and B (MenABCWY vaccine).
January 9, 2026 at 2:00 AM
Prior to 2023, the US had 4 licensed meningitis vaccines: 2 covered serogroups A, C, W, and Y (MenACWY vaccine) and 2 covered serogroup B (MenB vaccine).
In 2023, the FDA licensed two vaccines that cover A, C, W, Y and B (MenABCWY vaccine).
In 2023, the FDA licensed two vaccines that cover A, C, W, Y and B (MenABCWY vaccine).
21 had a question about her immunization record - turns out she never had MenB but I guess she’s right in line with the new guidance 🥲
January 6, 2026 at 2:11 AM
21 had a question about her immunization record - turns out she never had MenB but I guess she’s right in line with the new guidance 🥲
5/ We know what happens when vaccines move to shared decision-making. We have a decade of data.
MenACWY (routine): 89% uptake.
MenB (shared decision-making): 30% uptake.
Same disease. Same age group. Different recommendation category.
MenACWY (routine): 89% uptake.
MenB (shared decision-making): 30% uptake.
Same disease. Same age group. Different recommendation category.
January 5, 2026 at 8:23 PM
5/ We know what happens when vaccines move to shared decision-making. We have a decade of data.
MenACWY (routine): 89% uptake.
MenB (shared decision-making): 30% uptake.
Same disease. Same age group. Different recommendation category.
MenACWY (routine): 89% uptake.
MenB (shared decision-making): 30% uptake.
Same disease. Same age group. Different recommendation category.
and in the US, the disease is rarer here, and mostly impacts teens/young adults. also, there are some studies on how immunity of menB given in infancy wanes by the time they hit the higher risk years, so by waiting, they're hoping to get it when most effective
January 5, 2026 at 1:09 AM
and in the US, the disease is rarer here, and mostly impacts teens/young adults. also, there are some studies on how immunity of menB given in infancy wanes by the time they hit the higher risk years, so by waiting, they're hoping to get it when most effective
I believe a major factor of the UK's decisions on vaccination involves total cost, due to the NHS. So, they do more cost analyses in general. intiitally, the menB vaxx there was too expensive but then they got a much better rate from the manufacturer which made infant vaccination more cost effective
January 5, 2026 at 1:08 AM
I believe a major factor of the UK's decisions on vaccination involves total cost, due to the NHS. So, they do more cost analyses in general. intiitally, the menB vaxx there was too expensive but then they got a much better rate from the manufacturer which made infant vaccination more cost effective
I’m curious about why some countries (here is the UK’s) give a Meningitis B as babies and others (US) are like “16+ and only if necessary”
January 4, 2026 at 10:55 PM
I’m curious about why some countries (here is the UK’s) give a Meningitis B as babies and others (US) are like “16+ and only if necessary”
So where does the “wait 2 weeks” advice come from? Often from older COVID-era caution, local clinic policy, or concern about attributing AEs not from evidence that immune responses are impaired. There’s no data showing MenB or MenACWY⬇️ responses to flu or COVID vaccines if given closer together.
December 15, 2025 at 4:09 PM
So where does the “wait 2 weeks” advice come from? Often from older COVID-era caution, local clinic policy, or concern about attributing AEs not from evidence that immune responses are impaired. There’s no data showing MenB or MenACWY⬇️ responses to flu or COVID vaccines if given closer together.